Viridian Therapeutics, Inc./DE Debt Securities, Available-for-sale
Viridian Therapeutics, Inc./DE (VRDN) had Debt Securities, Available-for-sale of $816.54 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale $816.54M.
- 2026-03-31: Debt Securities, Available-for-sale $585.84M.
- 2025-12-31: Debt Securities, Available-for-sale $662.27M.
- 2025-09-30: Debt Securities, Available-for-sale $481.43M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $816.54M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $585.84M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $662.27M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $481.43M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $552.76M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $628.09M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $617.99M 10-K · filed 2026-02-26 | $714.05M 10-K · filed 2025-03-03 |
| 2024-09-30 | $736.61M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $564.45M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $609.93M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $463.25M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $308.57M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $333.40M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $366.40M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $424.45M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $431.22M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $161.09M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $175.33M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $196.87M 10-K · filed 2023-03-09 | |
| 2020-12-31 | $127.70M 10-K · filed 2022-03-11 | |
| 2019-12-31 | $2.00M 10-Q · filed 2020-11-12 | |
| 2019-09-30 | $9.00M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $19.90M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $32.80M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $29.90M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |